203 related articles for article (PubMed ID: 36647763)
1. Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy.
Su W; Tan M; Wang Z; Zhang J; Huang W; Song H; Wang X; Ran H; Gao Y; Nie G; Wang H
Angew Chem Int Ed Engl; 2023 Mar; 62(11):e202218128. PubMed ID: 36647763
[TBL] [Abstract][Full Text] [Related]
2. PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.
Ren X; Wang L; Liu L; Liu J
Front Immunol; 2024; 15():1392546. PubMed ID: 38638430
[TBL] [Abstract][Full Text] [Related]
3. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
5. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
6. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
[TBL] [Abstract][Full Text] [Related]
8. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
10. Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death.
Wang Z; Tan M; Su W; Huang W; Zhang J; Jia F; Cao G; Liu X; Song H; Ran H; Nie G; Wang H
J Med Chem; 2023 May; 66(9):6263-6273. PubMed ID: 37092695
[TBL] [Abstract][Full Text] [Related]
11. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
12. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Wu Y; Zhang C; Liu X; He Z; Shan B; Zeng Q; Zhao Q; Zhu H; Liao H; Cen X; Xu X; Zhang M; Hou T; Wang Z; Yan H; Yang S; Sun Y; Chen Y; Wu R; Xie T; Chen W; Najafov A; Ying S; Xia H
Nat Commun; 2021 Apr; 12(1):2346. PubMed ID: 33879767
[TBL] [Abstract][Full Text] [Related]
13. PROTACs: Promising approach for anticancer therapy.
Kaur SD; Bedi N; Kumar D; Kapoor DN
Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
[TBL] [Abstract][Full Text] [Related]
15. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1.
Cotton AD; Nguyen DP; Gramespacher JA; Seiple IB; Wells JA
J Am Chem Soc; 2021 Jan; 143(2):593-598. PubMed ID: 33395526
[TBL] [Abstract][Full Text] [Related]
16. PROTACs: Novel approach for cancer breakdown by breaking proteins.
Memon H; Patel BM
Life Sci; 2022 Jul; 300():120577. PubMed ID: 35487303
[TBL] [Abstract][Full Text] [Related]
17. PROTACs: Novel tools for improving immunotherapy in cancer.
Li S; Chen T; Liu J; Zhang H; Li J; Wang Z; Shang G
Cancer Lett; 2023 Apr; 560():216128. PubMed ID: 36933781
[TBL] [Abstract][Full Text] [Related]
18. Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
Yuan J; Li J; Shang M; Fu Y; Wang T
Biochem Biophys Res Commun; 2021 Jul; 561():187-194. PubMed ID: 34023785
[TBL] [Abstract][Full Text] [Related]
19. ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation.
Sun R; Meng Z; Lee H; Offringa R; Niehrs C
Cell Chem Biol; 2023 Jul; 30(7):739-752.e8. PubMed ID: 37321224
[TBL] [Abstract][Full Text] [Related]
20. Developments of PROTACs technology in immune-related diseases.
Wang C; Zhang Y; Deng J; Liang B; Xing D
Eur J Med Chem; 2023 Mar; 249():115127. PubMed ID: 36724631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]